Cover Image

Implementation and evaluation of a breast cancer disease model using real-world claims data in Germany from 2010 to 2020

Breast cancer is the leading cause of cancer-related mortality among women in Germany and worldwide. This retrospective claims data analysis utilizing data from AOK Baden-Wuerttemberg, a major statutory German health insurance provider, aimed to construct and assess a real-world data breast cancer d...

Full description

Saved in:
Bibliographic Details
Main Authors: Dannehl, Dominik (Author) , Au, Alexandra von (Author) , Engler, Tobias (Author) , Volmer, Léa (Author) , Gutsfeld, Raphael (Author) , Englisch, Johannes Felix (Author) , Hahn, Markus (Author) , Hawighorst, Sabine (Author) , Chaudhuri, Ariane (Author) , Bauer, Armin (Author) , Wallwiener, Markus (Author) , Ţăran, Florin-Andrei (Author) , Wallwiener, Diethelm (Author) , Brucker, Sara (Author) , Wallwiener, Stephanie (Author) , Hartkopf, Andreas (Author) , Dijkstra, Tjeerd Maarten Hein (Author)
Format: Article (Journal)
Language:English
Published: 2024
In: Cancers
Year: 2024, Volume: 16, Issue: 8, Pages: 1-15
ISSN:2072-6694
DOI:10.3390/cancers16081490
Online Access:Resolving-System, kostenfrei: https://doi.org/10.3390/cancers16081490
Resolving-System, kostenfrei: https://doi.org/10.25673/117367
Get full text
Author Notes:by Dominik Dannehl, Alexandra von Au, Tobias Engler, Léa Louise Volmer, Raphael Gutsfeld, Johannes Felix Englisch, Markus Hahn, Sabine Hawighorst-Knapstein, Ariane Chaudhuri, Armin Bauer, Markus Wallwiener, Florin-Andrei Taran, Diethelm Wallwiener, Sara Yvonne Brucker, Stephanie Wallwiener, Andreas Daniel Hartkopf and Tjeerd Maarten Hein Dijkstra
Description
Summary:Breast cancer is the leading cause of cancer-related mortality among women in Germany and worldwide. This retrospective claims data analysis utilizing data from AOK Baden-Wuerttemberg, a major statutory German health insurance provider, aimed to construct and assess a real-world data breast cancer disease model. The study included 27,869 female breast cancer patients and 55,738 age-matched controls, analyzing data from 2010 to 2020. Three distinct breast cancer stages were analyzed: Stage A (early breast cancer without lymph node involvement), Stage B (early breast cancer with lymph node involvement), and Stage C (primary distant metastatic breast cancer). Tumor subtypes were estimated based on the prescription of antihormonal or HER2-targeted therapy. The study established that 77.9% of patients had HR+ breast cancer and 9.8% HER2+; HR+/HER2- was the most common subtype (70.9%). Overall survival (OS) analysis demonstrated significantly lower survival rates for stages B and C than for controls, with 5-year OS rates ranging from 79.3% for stage B to 35.4% for stage C. OS rates were further stratified by tumor subtype and stage, revealing varying prognoses. Distant recurrence-free survival (DRFS) analysis showed higher recurrence rates in stage B than in stage A, with HR-/HER2- displaying the worst DRFS. This study, the first to model breast cancer subtypes, stages, and outcomes using German claims data, provides valuable insights into real-world breast cancer epidemiology and demonstrates that this breast cancer disease model has the potential to be representative of treatment outcomes.
Physical Description:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers16081490

Similar Items